FDA 483 - WES Pharma Inc. - November 21, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of WES Pharma Inc., a human drug manufacturer in Westminster, MD, revealed two significant observations. The firm was cited for using inappropriate equipment design, specifically tape on a multiuse blender, and for failing to follow quality control unit procedures, including inadequate labeling of controlled substances and untimely closure of deviation investigations. These findings indicate deficiencies in maintaining proper manufacturing and quality systems.
ID · c51662af-2e9d-4582-a9da-1b6e55d8dde7